Clinical Trial Update: A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)

View source ↗

Summary

This is a multi-center, single-arm, prospective non-interventional study to evaluate the safety and effectiveness of liposomal irinotecan (ONIVYDE) in combinati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• Liposomal irinotecan (Onivyde) (irinotecan liposome)

Snippet

Sponsor: Servier (Tianjin) Pharmaceutical Co. LTD. | Conditions: Metastatic Pancreatic Cancer | Status: NOT_YET_RECRUITING